175 related articles for article (PubMed ID: 22377563)
1. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.
Baumann KH; du Bois A; Meier W; Rau J; Wimberger P; Sehouli J; Kurzeder C; Hilpert F; Hasenburg A; Canzler U; Hanker LC; Hillemanns P; Richter B; Wollschlaeger K; Dewitz T; Bauerschlag D; Wagner U
Ann Oncol; 2012 Sep; 23(9):2265-2271. PubMed ID: 22377563
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
Campos SM; Penson RT; Matulonis U; Horowitz NS; Whalen C; Pereira L; Tyburski K; Roche M; Szymonifka J; Berlin S
Gynecol Oncol; 2013 Feb; 128(2):215-20. PubMed ID: 22885865
[TBL] [Abstract][Full Text] [Related]
3. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
Vergote IB; Garcia A; Micha J; Pippitt C; Bendell J; Spitz D; Reed N; Dark G; Fracasso PM; Ibrahim EN; Armenio VA; Duska L; Poole C; Gennigens C; Dirix LY; Leung AC; Zhao C; Soufi-Mahjoubi R; Rustin G
J Clin Oncol; 2013 Nov; 31(32):4060-6. PubMed ID: 24081946
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.
Biagi JJ; Oza AM; Chalchal HI; Grimshaw R; Ellard SL; Lee U; Hirte H; Sederias J; Ivy SP; Eisenhauer EA
Ann Oncol; 2011 Feb; 22(2):335-40. PubMed ID: 20705911
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
7. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
[TBL] [Abstract][Full Text] [Related]
8. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A
Ann Oncol; 2015 Jun; 26(6):1118-1123. PubMed ID: 25701452
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
11. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
Tomita Y; Shinohara N; Yuasa T; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Uemura H; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Dec; 40(12):1166-72. PubMed ID: 20713418
[TBL] [Abstract][Full Text] [Related]
12. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
14. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel BJ; Buss MK; Nattam SR; Hurteau J; Luo W; Curtis J; Whalen C; Kohn EC; Ivy SP; Matulonis UA
Ann Oncol; 2019 Apr; 30(4):551-557. PubMed ID: 30753272
[TBL] [Abstract][Full Text] [Related]
15. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Chan JK; Brady W; Monk BJ; Brown J; Shahin MS; Rose PG; Kim JH; Secord AA; Walker JL; Gershenson DM
Gynecol Oncol; 2018 Aug; 150(2):247-252. PubMed ID: 29921512
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Chekerov R; Hilpert F; Mahner S; El-Balat A; Harter P; De Gregorio N; Fridrich C; Markmann S; Potenberg J; Lorenz R; Oskay-Oezcelik G; Schmidt M; Krabisch P; Lueck HJ; Richter R; Braicu EI; du Bois A; Sehouli J; ;
Lancet Oncol; 2018 Sep; 19(9):1247-1258. PubMed ID: 30100379
[TBL] [Abstract][Full Text] [Related]
17. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ
Lancet Oncol; 2016 Mar; 17(3):378-388. PubMed ID: 26794930
[TBL] [Abstract][Full Text] [Related]
18. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Socinski MA; Novello S; Brahmer JR; Rosell R; Sanchez JM; Belani CP; Govindan R; Atkins JN; Gillenwater HH; Pallares C; Tye L; Selaru P; Chao RC; Scagliotti GV
J Clin Oncol; 2008 Feb; 26(4):650-6. PubMed ID: 18235126
[TBL] [Abstract][Full Text] [Related]
19. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Michaelson MD; Oudard S; Ou YC; Sengeløv L; Saad F; Houede N; Ostler P; Stenzl A; Daugaard G; Jones R; Laestadius F; Ullèn A; Bahl A; Castellano D; Gschwend J; Maurina T; Chow Maneval E; Wang SL; Lechuga MJ; Paolini J; Chen I
J Clin Oncol; 2014 Jan; 32(2):76-82. PubMed ID: 24323035
[TBL] [Abstract][Full Text] [Related]
20. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Hutterer M; Nowosielski M; Haybaeck J; Embacher S; Stockhammer F; Gotwald T; Holzner B; Capper D; Preusser M; Marosi C; Oberndorfer S; Moik M; Buchroithner J; Seiz M; Tuettenberg J; Herrlinger U; Wick A; Vajkoczy P; Stockhammer G
Neuro Oncol; 2014 Jan; 16(1):92-102. PubMed ID: 24311637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
